Cart (0 Items)
Your cart is currently empty.
View ProductsIstiratumab Biosimilar – Anti-ERBB3, IGF1R, CD221 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Istiratumab Biosimilar - Anti-ERBB3, IGF1R, CD221 mAb - Research Grade |
|---|---|
| Source | CAS 1509928-04-4 |
| Species | Homo sapiens |
| Expression system | Mammalian cells |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | ELISA,WB |
| Aliases /Synonyms | Istiratumab,MM-005,MM-141,ERBB3, IGF1R, CD221,anti-ERBB3, IGF1R, CD221 |
| Reference | PX-TA1381 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG1-kappa -[scFv]2 |
| Clonality | Monoclonal Antibody |
Description of Istiratumab Biosimilar - Anti-ERBB3/IGF1R/CD221 mAb - Research Grade
General information on Anti-ERBB3/IGF1R/CD221[Homo sapiens] (Istiratumab) Monoclonal Antibody
Istiratumab is investigated for the treatment of Front-line Metastatic Pancreatic Cancer.
Related products
Antigen
Receptor tyrosine-protein kinase erbB-3(ERBB3)Fc Tag
PX-P4725 210€
SIL
Reviews
Il n’y a pas encore d’avis.